BioXcel Therapeutics (BTAI) Reports Q4 Loss of $0.87/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to BioXcel Therapeutics (BTAI) Reports Q4 Loss of $0.87/sh

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 11, 2021 7:15 AM EST

New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation

TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021

RELEASE trial on track to report topline results in Q1 2021

Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021

Company... More